NCT07251829尚未招募2 期
Neoadjuvant Embolization and Cytoreduction to Ameliorate Radiotherapy Toxicity in Prostate Cancer
Srinivas Raman0 个研究点目标入组 35 人开始时间: 2026年2月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 35
- 主要终点
- Change in LUTS symptoms measured by the IPSS at 6 months post-PAE
研究概览
简要总结
The goal of this clinical trial is to find out whether prostate artery embolization (PAE) can help prevent or lessen urinary side effects caused by radiotherapy (RT) in people with prostate cancer, especially those who have larger prostates or urinary symptoms before treatment.
The main questions this study aims to answer are:
- Does PAE before RT reduce the severity of urinary side effects from RT?
- Does PAE affect the rates of genitourinary (GU) or gastrointestinal (GI) side effects after RT?
Researchers will look at changes in urinary symptoms from the start of the study to 6 months after PAE. They will also record any GU or GI side effects related to RT.
Participants will receive prostate artery embolization before starting radiotherapy, and complete questionnaires and assessments about GU and GI functions before and after treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed prostate adenocarcinoma with planned RT to the prostate
- •Baseline (pre-PAE) prostate volume ≥ 50 cc
- •Baseline (pre-PAE) IPSS ≥ 15
- •If planned or ongoing ADT and/or 5-alpha reductase inhibitor (5ARI), patient should be on therapy for at least 12 weeks, and meet prostate volume and pre-PAE IPSS criteria at the time of enrollment.
排除标准
- •Baseline (pre-PAE) IPSS storage/voiding ratio ≥ 1
- •Previous prostate treatment (TURP, Laser therapies, MISTs)
- •Chronic urinary retention requiring use of indwelling urinary catheter.
- •Neurogenic bladder or other neurological disorder that is impacting bladder function (e.g., multiple sclerosis, Parkinson's disease, spinal cord injuries, etc.).
- •Active urinary tract infections or recurrent urinary tract infections (>2/year), prostatitis, or interstitial cystitis.
- •Receipt of beta blockers, antihistamines, anticonvulsants, or antispasmodics within 1 week of study treatment AND patient has not been on the same drug dosage for 6 months with a stable voiding pattern.
- •Hypersensitivity reactions to contrast material not manageable with prophylaxis.
- •Glomerular filtration rates less than 40 mL/min (unless on dialysis).
- •Bilateral internal iliac arterial occlusion.
研究组 & 干预措施
PAE
Experimental
Neoadjuvant PAE before RT
干预措施: Prostatic Artery Embolization (Procedure)
结局指标
主要结局
Change in LUTS symptoms measured by the IPSS at 6 months post-PAE
时间窗: From enrollment to the 12 months after PAE
次要结局
- Rates of Grade ≥2 GU and GI RT toxicity as assessed by CTCAE v5.0(From enrollment to 12 months after PAE)
- Rates of PAE intraoperative and postoperative adverse events as assessed by Clavien-Dindo and CTCAE v5.0(From the start of PAE to 12 months after PAE)
- Prostatic Specific antigen (PSA) at 6 months post-PAE(From enrollment to 12 months after PAE)
- Change in prostate volume calculated by TRUS at 6 months post-PAE(From enrollment to 12 months after PAE)
- Change in peak urinary flow rate (Qmax, ml/s) at 6 months post-PAE(From enrollment to 6 months after PAE)
- Change in bladder and rectum mean RT dose from pre-PAE to pre-RT simulation scan(From pre-PAE simulation scan to pre-RT simulation scan)
- Urinary quality of life assessed by IPSS QoL scores(From enrollment to 12 months after PAE)
- Rate of local re-intervention for LUTS(From enrollment to 6 months after PAE)
- Erectile dysfunction assessed by the International Index of Erectile Function (IIEF-5) questionnaire(From enrollment to 12 months after PAE)
- Change in postvoid residual urine (PVR, ml) at 6 months post-PAE(From enrollment to 6 months after PAE)
研究者
Srinivas Raman
MD, FRCPC
British Columbia Cancer Agency
相似试验
已完成
不适用
Prostatic Arterial Embolization with SQUID (Ethylene Vinyl Alcohol Copolymer )Prostatic Hyperplasia, BenignNCT05395299Centre Hospitalier Universitaire de Nice12
撤回
不适用
Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in Prostate Cancer Patients Undergoing Radiation TherapyProstate CancerNCT05415696Stanford University
已完成
不适用
Prostate Artery Embolization for Symptomatic Benign Prostatic HyperplasiaBenign Prostate HyperplasiaNCT02822924Chinese University of Hong Kong82
Unknown
不适用
Taiwan ACE Beads for Embolization Therapy in Symptomatic Benign Prostatic HyperplasiaBenign Prostatic Hyperplasia (BPH)Lower Urinary Tract SymptomNCT03239652National Cheng-Kung University Hospital12
已完成
不适用
Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)Benign Prostatic HyperplasiaNCT02930889University of Minnesota21